These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 21482945

  • 1. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T.
    Neurology; 2011 Apr 12; 76(15):1310-5. PubMed ID: 21482945
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W.
    Brain; 2008 Nov 12; 131(Pt 11):3072-80. PubMed ID: 18945724
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ.
    JAMA Neurol; 2013 Sep 01; 70(9):1110-7. PubMed ID: 23897062
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D, Yu Y, Yan W, Dai Q, Xu Z, Chu L.
    Pediatr Neurol; 2014 Aug 01; 51(2):255-8. PubMed ID: 25079575
    [Abstract] [Full Text] [Related]

  • 9. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA.
    Arch Neurol; 2008 Nov 01; 65(11):1443-8. PubMed ID: 18779415
    [Abstract] [Full Text] [Related]

  • 10. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
    Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E.
    Mult Scler; 2012 Jul 01; 18(7):1022-6. PubMed ID: 22261118
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
    Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA.
    Mult Scler; 2011 Oct 01; 17(10):1225-30. PubMed ID: 21622594
    [Abstract] [Full Text] [Related]

  • 13. An open label study of the effects of rituximab in neuromyelitis optica.
    Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C.
    Neurology; 2005 Apr 12; 64(7):1270-2. PubMed ID: 15824362
    [Abstract] [Full Text] [Related]

  • 14. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
    Gredler V, Mader S, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A.
    J Neurol Sci; 2013 May 15; 328(1-2):77-82. PubMed ID: 23522498
    [Abstract] [Full Text] [Related]

  • 15. [Neuromyelitis optica in children. Two case reports].
    Tosello B, Halbert C, Mancini J, Chabrol B, Boucraut J, Milh M.
    Arch Pediatr; 2012 Aug 15; 19(8):827-31. PubMed ID: 22789744
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of rituximab in pediatric neuromyelitis optica.
    Mahmood NA, Silver K, Onel K, Ko M, Javed A.
    J Child Neurol; 2011 Feb 15; 26(2):244-7. PubMed ID: 21183724
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
    Weinfurtner K, Graves J, Ness J, Krupp L, Milazzo M, Waubant E.
    J Child Neurol; 2015 Sep 15; 30(10):1366-70. PubMed ID: 25387545
    [Abstract] [Full Text] [Related]

  • 19. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M, Romero G, Bas J, Ticchioni M, Rosenthal M, Lacroix R, Brunet C, Rico A, Pelletier J, Audoin B, Lebrun C.
    J Neurol Sci; 2017 Feb 15; 373():335-338. PubMed ID: 28131216
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.